COMPANY
Seaport Therapeutics
We are developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. From company website Source · Oct 12, 2026
Since the raise (2024-10-31, SEC Form D): 8 of 8 open jobs were first seen after it.
Hiring
| Title | Location (from posting) | Employer posted | First seen |
|---|---|---|---|
| Associate Director, Regulatory Affairs | Boston, MA | Oct 13, 2026 | Oct 14, 2026 |
| Associate Director, Drug Substance Process Development | Boston, MA | Sep 15, 2026 | Oct 9, 2026 |
| Associate Director, Program Manager | Boston, MA | Sep 3, 2026 | Oct 9, 2026 |
| Bio-Analytical Co-op-Northeastern Students | Boston, MA | Aug 20, 2026 | Oct 9, 2026 |
| Clinical Trial Manager | Boston, MA | Jul 27, 2026 | Oct 9, 2026 |
Timeline
- Board tracked Radar started tracking this company’s job board (8 open jobs at last check). source ↗
- Trial start Phase 2: An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study source ↗
- Trial start Phase 2: A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study) source ↗
Upcoming milestones
- 2027-03 (ESTIMATED) · Phase 2 · A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study) · NCT07065240
- 2027-05 (ESTIMATED) · Phase 2 · An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study) · NCT07161700
Open jobs 8
| Title | Location (from posting, not HQ) | Employer posted | First seen | Level |
|---|---|---|---|---|
| Associate Director, Regulatory Affairs | Boston, MA | Oct 13, 2026 | Oct 14, 2026 | Senior |
| Associate Director, Drug Substance Process Development | Boston, MA | Sep 15, 2026 | Oct 9, 2026 | Senior |
| Associate Director, Program Manager | Boston, MA | Sep 3, 2026 | Oct 9, 2026 | Senior |
| Bio-Analytical Co-op-Northeastern Students | Boston, MA | Aug 20, 2026 | Oct 9, 2026 | Entry |
| Clinical Trial Manager | Boston, MA | Jul 27, 2026 | Oct 9, 2026 | Mid |
| Director, Clinical Quality Assurance | Boston, MA | Jun 17, 2026 | Oct 9, 2026 | Senior |
| Senior Director, Analytical Research & Development | Boston, MA | Apr 8, 2026 | Oct 9, 2026 | Senior |
| Executive Director/Vice President, Clinical Development | Boston, MA | Jan 9, 2026 | Oct 9, 2026 | Executive |
Clinical trials (lead sponsor) 2
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT07065240 | A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study) | Phase 2 | Recruiting | Jun 19, 2025 | 2027-03 (estimated) |
| NCT07161700 | An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study) | Phase 2 | Enrolling by invitation | Sep 2, 2025 | 2027-05 (estimated) |
Raises and investors new
- Raise Private raise (SEC Form D): $225.9M sold of $226.0M offered; issuer “Seaport Therapeutics, Inc.”. Verified from the SEC filing. SEC filing ↗
- InvestorListed in the portfolio of ARCH Venture Partners (captured Oct 12, 2026). portfolio page ↗
- InvestorListed in the portfolio of Sofinnova Investments (captured Oct 12, 2026). portfolio page ↗
Connect
See your connections at Seaport Therapeutics on LinkedIn (search by name, results not checked)